Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial

Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab

(2014) Shoko Nakajima et al.   Modern Rheumatology

Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis

(2013) F. Uettwiller et al.   JOURNAL OF RHEUMATOLOGY

Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan

(2012) Shumpei Yokota et al.   ANNALS OF THE RHEUMATIC DISEASES

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathways for Bone Loss in Inflammatory Disease

(2012) Tobias Braun et al.   Current Osteoporosis Reports

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis

(2010) Edward H. Giannini et al.   ARTHRITIS AND RHEUMATISM

Development and validation of a composite disease activity score for juvenile idiopathic arthritis

(2009) Alessandro Consolaro et al.   ARTHRITIS AND RHEUMATISM

The IGF system and cytokine interactions and relationships with longitudinal growth in prepubertal patients with cystic fibrosis

(2008) Maria E. Street et al.   CLINICAL ENDOCRINOLOGY

Growth Velocity and Interleukin 6 Concentrations in Juvenile Idiopathic Arthritis

(2008) Leticia S. Souza et al.   JOURNAL OF RHEUMATOLOGY